Vivianne Jakobsson

Singapore, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 13, 2025

Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG/[18F]AlF-NOTA-FAPI-04 PET/CT in renal cell carcinoma.

Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG/[18F]AlF-NOTA-FAPI-04 PET/CT in renal cell carcinoma.

Journal: Theranostics
Published: March 01, 2025

Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.

Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.

Journal: Clinical nuclear medicine
Published: December 03, 2024

Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics.

Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 18, 2024

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.

Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.

Journal: Seminars in nuclear medicine
Published: May 25, 2024

Engineered Antibodies as Cancer Radiotheranostics.

Engineered Antibodies as Cancer Radiotheranostics.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 05, 2024

First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors.

First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors.

Journal: Theranostics
Published: January 21, 2024

Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013.

Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013.

Journal: European journal of nuclear medicine and molecular imaging
Published: December 06, 2023

Long-term Nephrotoxicity after PRRT: Myth or Reality.

Long-term Nephrotoxicity after PRRT: Myth or Reality.

Journal: Theranostics
Published: November 22, 2023

A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging.

A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 16, 2023

Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.

Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 02, 2023

A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.

A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.

Journal: Clinical nuclear medicine
Published: September 08, 2023
Showing 1-12 of 15

Last Updated: 09/26/2026